For instance, in adjuvant and neoadjuvant chemotherapy responses, they correlate with survival benefit in human epidermal growth factor receptor 2 (HER2)-positive breast cancer and triple-negative breast cancer (TNBC) [7,8], whereas in luminal HER2-negative BC increased TILs are an adverse prognostic factor for survival [8]. Here, ERBB2 is linked to breast carcinoma.